TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1347280
Drug: Sulphasalazine 1
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulphasalazine 1 g bd
Study: 26555602
Drug: Algisyl with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algisyl with standard medical therapy (SMT)
Study: 19484969
Drug: Euglycemic-hyperinsulinemic clamp
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycemic-hyperinsulinemic clamp after 2 week insulin intensive treatment
Study: 16118599
Drug: Metronidazole gel
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole gel
Study: 9361167
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice daily (RAN)
Study: 31060106
Drug: Activities of
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activities of Daily Living (ADL) II (disabled only in some instrumental ADL)
Study: 27245206
Drug: Galactogogue containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galactogogue containing silymarin-phosphatidylserine and galega, 5 g/day (galactogogue group, GG)
Study: 9846707
Drug: Vaginal PGE2
Normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vaginal PGE2 2 mg, two doses at 6-hour intervals
Study: 26480547
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (estazolam 1mg before bed, oryzanol 20 mg three times a day) for 4 weeks
Study: 26480547
Drug: Integrated acupuncture
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated acupuncture and medication (same as above) for 4 weeks
Study: 10752844
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (NO)
Study: 29134517
Drug: Subcutaneous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous ketamine 1 mg·kg‐1 (n=30)
Study: 21124304
Drug: D-cycloserine (DCS)
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D-cycloserine (DCS) 1000 mg
Study: 21124304
Drug: Glycine 0.3
Normalized name: FreAmine 6.9 (alanine 0.4 GM / arginine 0.58 GM / cysteine 0.02 GM / glycine 0.33 GM / histidine 0.16 GM / isoleucine 0.76 GM / leucine 1.37 GM / lysine (as lysine acetate) 0.58 GM / methionine 0.25 GM / phenylalanine 0.32 GM / proline 0.63 GM / serine 0.33 GM / threonine 0.2 GM / tryptophan 0.09 GM / valine 0.88 GM) per 100 ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycine 0.3 g/kg
Study: 1773908
Drug: Dimethindene maleate
Normalized name: dimethindene maleate
DrugBank: Dimetindene (DB08801)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimethindene maleate 6 mg
Study: 1636805
Drug: Acute treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute treatment with imipramine (6 months)
Study: 19691829
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of ciprofloxacin or 7 days of empirical beta-lactams +/− gentamicin intravenously with early switch to oral ciprofloxacin followed by 7 days of blinded placebo
Study: 31377905
Drug: Intravitreal anti-VEGF
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal anti-VEGF injection (bevacizumab 1.25 mg or ranibizumab 0.5 mg)
Study: 31377905
Drug: Dexamethasone implant
Normalized name: dexamethasone Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone implant (0.7 mg)
Study: 11912261
Drug: AMG 073
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 073 (50 mg)
Study: 11912261
Drug: AMG 073
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 073 (100 mg)
Study: 17921373
Drug: High-fiber cereal
Normalized name: FIBERMED HIGH-FIBER SUPPLEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fiber cereal (HF; 33 g insoluble fiber)
Study: 17507703
Drug: As-needed combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: As-needed combination therapy
Study: 12911833
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 1000-2000 micro g/day
Study: 26226139
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (4 g/d)
Study: 12921494
Drug: Zolmitriptan nasal
Normalized name: Zolmitriptan Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan nasal spray 2.5mg
Study: 27770454
Drug: Oral nutrition
Normalized name: BAGS/TUBES/SUPPLIES FOR ORAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutrition alone (group B; n = 83)
Study: 27770454
Drug: Postoperative total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative total parenteral nutrition (group A; n = 74)
Study: 18312522
Drug: Ketamine 1
Normalized name: ketamine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 1 mg x kg(‐1)
Study: 1492226
Drug: Etoposide in
Normalized name: etoposide Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide in combination with anthracycline
Study: 2179277
Drug: nicardipine 20
Normalized name: nicardipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nicardipine 20 mg tid
Study: 12847735
Drug: Topical and
Normalized name: norgestimate and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical and oral L-phenylalanine (100 mg/Kg/day and gel at 10%) with 0.025% clobetasol propionate at night, sunlight or UVA exposure
Study: 27902588
Drug: Normally therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normally therapy method (Control)
Study: 18182463
Drug: Hydrocortisone infusion
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone infusion (3 microg/kg/min for 6 hours)
Study: 8432776
Drug: Saline control
Normalized name: GLYCERIN 0.53 g in 1 mL CUTANEOUS INJECTION [Glycerol-Saline Control]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline control infusion
Study: 22336574
Drug: Hydrocortisone infusion
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone infusion
Study: 21842274
Drug: frovatriptan 2.5
Normalized name: frovatriptan 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: frovatriptan 2.5 mg
Study: 14676459
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg CEE and 2.5 mg MPA every other day
Study: 10525751
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg sulpiride
Study: 27578252
Drug: Orange-flavoured beverage
Normalized name: Orange
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orange-flavoured beverage with low dose OPF (2.5 g)
Study: 27400947
Drug: Cabozantinib 60
Normalized name: cabozantinib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 60 mg once per day
Study: 27400947
Drug: Prednisone 5
Normalized name: prednisone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 5 mg twice per day
Study: 9346426
Drug: Acetazolamide (Acz)
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide (Acz) administration
Study: 8389536
Drug: Culture preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culture preparations of skin specimens from primary EM patients
Study: 8389536
Drug: Culture preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culture preparations of skin specimens from secondary EM patients
Study: 31954837
Drug: Stepwise CMD
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Stepwise CMD risk assessment followed by individualized treatment
Study: 29084522
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 10,000 IU daily
Study: 2968374
Drug: Trioxsalen bath-PUVA
Normalized name: Trioxsalen
DrugBank: Trioxsalen (DB04571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trioxsalen bath-PUVA treatment (control for methoxsalen)
Study: 28477440
Drug: Intravitreous fluocinolone
Normalized name: Fluocinolone Acetonide Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreous fluocinolone acetonide implant
Study: 14623061
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg tibolone
Study: 23045348
Drug: BoNT-A injection
Normalized name: BoNT/A-DS
DrugBank: LetibotulinumtoxinA (DB16820)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT-A injection into the soleus muscle
Study: 12848776
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg DEX hydro-bromide
Study: 12124547
Drug: Control (G-1)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (G-1)
Study: 31307505
Drug: 3.75 mg
Normalized name: zopiclone 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg midazolam
Study: 9603657
Drug: Systemic liarozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic liarozole 75 mg BID for at least 2 months
Study: 2271089
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (6 g daily for 1 month)
Study: 23227307
Drug: Low-dose Tacrolimus
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Tacrolimus (LD) with EC-MPS 720mg bid
Study: 18396035
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg morphine + 5 mg ketamine/bolus (MK group)
Study: 3904373
Drug: Intravenous milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous milrinone (25, 50, and 75 micrograms/kg)
Study: 8528973
Drug: Floxuridine (FUDR)
Normalized name: Floxuridine
DrugBank: Floxuridine (DB00322)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Floxuridine (FUDR) 0.525 mg/kg/day + L-folinic acid (L-FA) 10 mg/m2/day
Study: 25018648
Drug: Desvenlafaxine 100
Normalized name: desvenlafaxine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine 100 mg/day
Study: 29593018
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (250 mg daily for 5 days)
Study: 8680672
Drug: Albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol
Study: 16104039
Drug: Aprepitant regimen
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant regimen (Day 1: APR 125 mg, OND 8 mg, DEX 12 mg before chemotherapy and OND 8 mg 8 hrs later; Days 2-3: APR 80 mg every day)
Study: 23427386
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (performed three times/week from postoperative day 7 until postoperative day 21)
Study: 15790982
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone 400 microg daily for 12 weeks
Study: 15790982
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (non-smokers receiving inhaled beclomethasone)
Study: 12966473
Drug: Ketorolac 30
Normalized name: ketorolac 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 30 mg intravenously
Study: 26860802
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) treatment
Study: 23218184
Drug: FAc implants
Normalized name: 4'-Thio-fac
DrugBank: 4'-Thio-fac (DB16071)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAc implants
Study: 22333199
Drug: Propofol TCI
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol TCI plus a low concentration of sevoflurane inhalation induction (Group A)
Study: 28724657
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplements (LNS-PL) 20 g/d, 118 kcal
Study: 25199526
Drug: Physical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Therapy (2x/week for 6 weeks, followed by 6 weeks of monitored home exercise)
Study: 10534727
Drug: Recombinant hepatitis
Normalized name: Recombinant hepatitis B human immunoglobulin
DrugBank: Lenvervimab (DB17814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hepatitis B vaccine (20 microg/dose) given in months 0, 1, and 6 to group I (26 patients)
Study: 24552155
Drug: Albiglutide 30
Normalized name: ALBIGLUTIDE 30MG/0.5ML INJ PEN 0.5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albiglutide 30 mg biweekly
Study: 14752617
Drug: Taurine supplementation
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine supplementation (3 g/day)
Study: 1323160
Drug: Sodium stibogluconate
Normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium stibogluconate combined with oral verapamil
Study: 1093604
Drug: Topical cephaloridine
Normalized name: cephaloridine
DrugBank: Cefaloridine (DB09008)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cephaloridine
Study: 19168019
Drug: Desmopressin tablets
Normalized name: desmopressin Sublingual Tablet
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Desmopressin tablets (0.2 or 0.4 mg)
Study: 11719353
Drug: G-BM
Normalized name: Glatiramer Acetate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: G-BM
Study: 28319696
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity without treatment rationale
Study: 28319696
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity with treatment rationale
Study: 23475289
Drug: Isoflavone 70
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone 70 mg/day for 12 weeks
Study: 30993350
Drug: Deep extubation
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep extubation in the lateral position (group L)
Study: 12474549
Drug: Hormone-replacement therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone-replacement therapy (HRT)
Study: 17259872
Drug: HA vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA vaccine (HAVRIX; Glaxo SmithKline) 720 EL.U., administered in group 2 at ages 12 and 18 months
Study: 17259872
Drug: HA vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA vaccine (HAVRIX; Glaxo SmithKline) 720 EL.U., administered in group 3 at ages 15 and 21 months
Study: 8030449
Drug: Combined hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined hormonal oral contraceptive containing 75 μg gestodene plus 30 μg ethinyl estradiol
Study: 19399705
Drug: Low-dose (LD)
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose (LD) nifedipine; 10 mg, up to four doses every 15 minutes, daily 60 to 80 mg slow-release nifedipine for 48 hours followed by 60 mg daily until 36 weeks
Study: 27101674
Drug: Montelukast sodium
Normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast sodium tablets combined with budesonide nasal spray and desloratadine citrate disodium tablets for 4 weeks
Study: 8198235
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with alginate-conjugated extract of Parietaria judaica
Study: 27979383
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2 every 3 weeks
Study: 21953376
Drug: 1.6 g
Normalized name: GLYCERIN 1241.6 g in 1 L TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 g CMC-001 (manganese-based contrast agent)
Study: 2365458
Drug: Leish vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leish vaccine 5
Study: 28387919
Drug: Intensive drugs
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive drugs (Control)
Study: 8910180
Drug: Lidocaine 30
Normalized name: lidocaine 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 30 mg
Study: 23223105
Drug: Lidocaine 45
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine 45 mg
Study: 12399193
Drug: MPL-containing vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPL-containing vaccine
Study: 9794569
Drug: Nifedipine retard
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine retard (10‐40 mg twice daily)
Study: 7655643
Drug: Octreotide (OCT)
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Octreotide (OCT) administration (300 to 600 micrograms/day for 1 month)
Study: 15377319
Drug: SB-220453 40
Normalized name: SBS-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-220453 40 mg
Study: 31586667
Drug: Oral amoxicillin
Normalized name: amoxicillin Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin
Study: 21727006
Drug: Ibandronate 6
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 6 mg infused over 60 min
Study: 7604951
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray 200 micrograms once daily
Study: 14998068
Drug: Naratriptan 1
Normalized name: naratriptan 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naratriptan 1 mg
Study: 24717626
Drug: Tadalafil 10
Normalized name: tadalafil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 10 mg daily for 12 weeks
Study: 1097470
Drug: Minocycline 100
Normalized name: minocycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 100 mg twice daily
Study: 1097470
Drug: Tetracycline 250
Normalized name: tetracycline 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline 250 mg six-hourly
Study: 28083972
Drug: SGLT2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT2 inhibitors (including canagliflozin, dapagliflozin, empagliflozin)
Study: 27325864
Drug: Regorafenib 160
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 160 mg orally on days 1 to 21 of each 28-day cycle until disease progression or prohibitive adverse events occurred.
Study: 24695091
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg/day for 14 days
Study: 7581968
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (rhGH) replacement therapy for 6 months
Study: 31607143
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (24-hour mean systolic BP ≤130 mm Hg)
Study: 18972429
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) chemoradiation
Study: 28510491
Drug: FP pMDI
Normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP pMDI (Flixotide®) 100 μg b.i.d. with Volumatic® spacer
Study: 11813931
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg BID (IR tablets)
Study: 9217822
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of betamethasone-17-valerate (once a day) and tretinoin (once a day)
Study: 23716765
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg
Study: 1386976
Drug: Ondansetron 12
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron 12 mg
Study: 12069102
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of Q10 (maximum daily dose recommended)
Study: 12069102
Drug: Q10 with
Normalized name: Coenzyme Q10/Red Yeast Rice 60 MG-600 MG Oral Capsule, Liquid Filled [COQ10 WITH RED YEAST RICE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q10 with minor vitamin E dose
Study: 7481863
Drug: Paclitaxel plus
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel plus carboplatin (175 mg/m2 in a 3-hour infusion)
Study: 21762358
Drug: Azilsartan medoxomil
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan medoxomil 40 mg and 80 mg